L. Domínguez-Domínguez

发表

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

G. Bloomfield, M. Kozal, K. Tashima, 2020, The Journal of infectious diseases.

Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients

F. Pulido, R. Rubio, O. Bisbal, 2020, Enfermedades infecciosas y microbiologia clinica (English ed.).

Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection

C. Lumbreras, F. Pulido, R. Rubio, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients.

F. Pulido, R. Rubio, O. Bisbal, 2020, Enfermedades infecciosas y microbiologia clinica.

Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients

V. Briz, M. López-Huertas, M. Coiras, 2020, Journal of clinical medicine.

HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

J. Benito, J. Alcamí, V. Briz, 2019, Scientific Reports.

Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

M. Rava, S. Moreno, A. Antela, 2021, PloS one.

Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients

I. Jiménez-Nácher, F. Pulido, J. González-García, 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients.

I. Jiménez-Nácher, F. Pulido, J. González-García, 2019, Enfermedades infecciosas y microbiologia clinica.

Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.

Mayur R Gamit, J. Canny, M. Beadsworth, 2022, The Lancet. Infectious diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV

J. Lundgren, J. Reekie, B. Grund, 2022, AIDS (London, England).

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.

J. Arribas, R. Delgado, V. Moreno, 2020, The Journal of antimicrobial chemotherapy.

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

J. Arribas, R. Delgado, V. Moreno, 2020, EBioMedicine.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU

D. Podzamczer, B. Clotet, E. Negredo, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).

B. Rodés, J. Arribas, R. Delgado, 2021, The Journal of antimicrobial chemotherapy.

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004–2018

D. Podzamczer, J. Olalla, M. Rava, 2022, BMC Infectious Diseases.

Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

E. Ribera, M. Rava, S. Moreno, 2021, AIDS.

Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients

V. Briz, G. Cuevas, P. Ryan, 2021, Biomedicines.

Hepatocellular carcinoma risk in hepatitis C stage‐3 fibrosis after sustained virological response with direct‐acting antivirals

C. Fernández-Rodríguez, L. Bonet, G. Cuevas, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy.

L. Domínguez-Domínguez, Á. Marchán-López, M. E. Jarrín-Estupiñán, 2016, Journal of hepatology.

Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection

C. Lumbreras, F. Pulido, R. Rubio, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV

J. Lundgren, J. Reekie, B. Grund, 2022, AIDS.